Generic drug names and social welfare

Journal of Health Politics, Policy and Law

Volumn 38, Issue 3, 2013, Pages 573-598

  Lobo, Félix ^a   Feldman, Roger ^b  

^a UNIVERSIDAD CARLOS III DE MADRID   (Spain)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG;

ARTICLE; DRUG LABELING; HUMAN; INTERNATIONAL COOPERATION; MEDICATION ERROR; NOMENCLATURE; PATIENT SAFETY; SOCIAL WELFARE; PREVENTION AND CONTROL;

DRUG LABELING; DRUGS, GENERIC; HUMANS; INTERNATIONALITY; MEDICATION ERRORS; PATIENT SAFETY; SOCIAL WELFARE; TERMINOLOGY AS TOPIC;

EID: 84877977875     PISSN: 03616878     EISSN: 15271927     Source Type: Journal    
DOI: 10.1215/03616878-2079505     Document Type: Article

References (75)

1. Allan, F. M. 1974. "Standardization of Drug Names." Journal of the American Medical Association 229, no. 5: 541-43.
2. American Medical Association. 1964. "Editorial: Drug Names." Journal of the American Medical Association 190, no. 6: 542.
3. American Medical Association. 2012. "United States Adopted Names." www.ama-assn.org/ama/pub/physician-resources/medical-science/united-states-adopted-names-council.page (accessed December 25, 2012).
4. Asociación Española de Medicamentos Genéricos. 2011. "Genéricos en España." www.aeseg.es/ (accessed April 22, 2011).
5. Assistant Secretary for Planning and Evaluation. 2010. Expanding the Use of Generic Drugs. Washington, DC: US Department of Health and Human Services.
6. Berndt, E. R., and M. L. Aitken. 2010. "Brand Loyalty, Generic Entry, and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation." NBER Working Paper No. 16431 (October). Cambridge, MA: National Bureau of Economic Research.
7. Ching, A. T. 2010. "A Dynamic Oligopoly Structural Model for the Prescription Drug Market after Patent Expiration." International Economic Review 51, no. 4: 1175-207.
8. Cohen, M. R., G. Di Domizio, and R. E. Lee Jr. 2007. "The Role of Drug Names in Medication Errors." In Medication Errors, 2nd ed., edited by M. R. Cohen, 87-110. Washington, DC: American Pharmacists Association.
9. Collectif Europe et Médicament Editorial Staff. 2003. "We Don't Want Secret Remedies." www.mutualite.fr/web/frameset.nsf/LookPageInter/infosante_medic_euro_remede/$file/remede.pdf.
10. Consumer Reports. 2001. "The Stalling Game." Consumer Reports 66, no. 7. www.accessmylibrary.com/coms2/summary_0286-10646962_ITM.
11. Cook, A. 1998. How Increased Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry. Washington, DC: US Congressional Budget Office. www.fda.gov/ohrms/dockets/dailys/04/June04/061404/03p-0029-bkg0001-Ref-15-vol3.pdf.
12. Council of Europe, Expert Group on Safe Medication Practices. 2006. Creation of a Better Medication Safety Culture in Europe: Building Up Safe Medication Practices; Report. Strasbourg: Council of Europe.
13. Darby, M. R., and E. Karni. 1973. "Free Competition and the Optimal Amount of Fraud." Journal of Law and Economics 16, no. 1: 67-88.
14. Duncan, J. M. 2002. "Closing the Gaps in Hatch-Waxman: Assuring Greater Access to Affordable Pharmaceuticals." Statement by Janell Mayo Duncan of the Consumers Union before the United States Senate, Health, Education, Labor and Pensions Committee, May 8. www.consumersunion.org/health/genericdc.htm.
15. Espín, J., and J. Rovira. 2007. Analysis of Differences and Commonalities in Pricing and Reimbursement Systems in Europe. Brussels: European Commission.
16. European Generics Association. 2011. "The Role of Generic Medicines in Europe." http://198.170.119.137/gen-geneurope.htm (accessed December 23, 2012).
17. European Union. 2004. "Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community Code relating to Medicinal Products for Human Use." Official Journal of the European Union (November 28): 67-128.
18. European Union. 2011. "Commission Regulation (EU) No. 1006/2011 of 27 September 2011 amending Annex I to Council Regulation (EEC) No. 2658/87 of 23 July 1987 on the Tariff and Statistical Nomenclature and on the Common Customs Tariff." Official Journal of the European Union 54 (L282, October 28): 1-912.
19. Gaither, C., et al. 2001. "Consumers' Views on Generic Medicines." Journal of the American Pharmacists Association 41, no. 5: 729-36.
20. Ganther, J. M., and D. H. Kreling. 2000. "Consumer Perceptions of Risk and Required Cost Savings for Generic Prescription Drugs." Journal of the American Pharmacists Association 40, no. 3: 378-83.
21. Goddard, J. 1967. FDA Commissioner's Statement before the US Congress, 1967-1973: Part 2: 792.
22. Hansen, R. A., N. J. Shaheen, and J. C. Schommer. 2005. "Factors Influencing the Shift of Patients from One Proton Pump Inhibitor to Another: The Effect of Direct-to -Consumer Advertising." Clinical Therapeutics 27, no. 9: 1478-87.
23. Hellström, J., and N. Rudholm. 2010. "Uncertainty in the Generic versus Brand Name Prescription Decision." Empirical Economics 38, no. 3: 503-21.
24. Hoffman, J. M., and S. M. Proulx. 2003. "Medication Errors Caused by Confusion of Drug Names." Drug Safety 26, no. 7: 445-52.
25. Hollis, A. 2002. "The Importance of Being First: Evidence from Canadian Generic Pharmaceuticals." Journal of Health Economics 11: 723-34.
26. IMS Institute for Healthcare Informatics. 2011. "The Use of Medicines in the United States: Review of 2010." Parsippany, NJ: IMS Institute for Healthcare Informatics. www.imshealth.com/imshealth/Global/Content/IMS%20Institute/Documents/IHII_UseOfMed_report%20.pdf.
27. Katz, M., and C. Shapiro. 1985. "Network Externalities, Competition, and Compatibility." American Economic Review 75, no. 3: 424-40.
28. Kesselheim, A. S., et al. 2008. "Clinical Equivalence of Generic and Brand Name Drugs Used in Cardiovascular Disease: A Systematic Review and Meta-Analysis." Journal of the American Medical Association 300: 2514-26.
29. Kindleberger, C. P. 1983. "Standards as Public, Collective, and Private Goods." Kyklos 36, no. 3: 377-96.
30. Kindleberger, C. P. 1986. "International Public Goods without International Government." American Economic Review 76, no. 1: 1-13.
31. Kullman, D. 2011. "Pharmaceutical System in the UK." Paper presented to the PPRI Conference, Vienna, September 30. http://whocc.goeg.at/Downloads/Conference2011/PraesentationenPPRIKonferenz/Day2_morning_Festsaal_0945_Kullman.pdf.
32. Leffler, K. B. 1981. "Persuasion or Information? The Economics of Prescription Drug Advertising." Journal of Law and Economics 24: 45-74.
33. Les Entreprises du Médicament. 2012. "L'industrie: Chiffre d'affaires: L'economie du médicaments." June 28. www.leem.org/article/chiffre-daffaires (accessed December 23, 2012).
34. López-Casasnovas, G., and J. Puig-Junoy. 2000. "Review of the Literature on Reference Pricing." Health Policy 54, no. 2: 87-123.
35. Medicines and Healthcare Products Regulatory Agency (MHRA). 2003. "Changing Substance Names from Bans to Rinns: Instructions to Marketing Authorisation (MA) Holders." Mail: The MHRA Updating Service for Medicines 138 (July-August): 4-6.
36. Mestre Ferrándiz, J. 1999. "The Impact of Generic Goods in the Pharmaceutical Industry." Health Economics 8, no. 7: 599-612.
37. Mintz, M. 1962. "'Heroine' of FDA Keeps Bad Drug Off of Market." Washington Post, July 15.
38. Mott, D. A., and R. R. Cline. 2002. "Exploring Generic Drug Use Behavior: The Role of Prescribers and Pharmacists in the Opportunity for Generic Drug Use and Drug Substitution." Medical Care 40, no. 8: 662-74.
39. Mrazek, M., and R. Frank. 2004. "The Off-Patent Pharmaceutical Market." In Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity, and Quality, edited by E. Mossialos, M. Mrazek, and T. Walley, 245-59. Maidenhead, UK: Open University Press.
40. National Economic Research Associates. 1999. "Policy Relating to Generic Medicines in the OECD." www.ifarma.org/web/wp-content/uploads/2009/02/farmacosgenericos.pdf.
41. Nelson, P. 1970. "Information and Consumer Behavior." Journal of Political Economy 78, no. 2: 311-19.
42. Nelson, P. 1974. "Advertising as Information." Journal of Political Economy 82, no. 4: 729-54.
43. New York Times. 1989. "F.D.A. Chief Says Most Generics Meet Standards." November 18.
44. Organisation for Economic Co-operation and Development (OECD). 2008. Pharmaceutical Pricing Policies in a Global Market. Paris: OECD Health Policy Studies.
45. Pharmaceutical Research and Manufacturers of America (PhRMA). 2002. "Delivering on the Promise of Pharmaceutical Innovation: The Need to Maintain Strong and Predictable Intellectual Property Rights." Submitted to the Federal Trade Commission and the Department of Justice Antitrust Division, April 22. www.ftc.gov/os/comments/intelpropertycomments/phrma020422.pdf.
46. PHIS Database. 2011. "Database." WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies. http://whocc.goeg.at.
47. Posner, R. A. 2005. "Intellectual Property: The Law and Economics Approach." Journal of Economic Perspectives 19, no. 2: 57-73.
48. Rados, C. 2005. "Drug Name Confusion: Preventing Medication Errors." FDA Consumer Magazine 39, no. 4. http://permanent.access.gpo.gov/lps1609/www.fda.gov/fdac/features/2005/405_confusion.html.
49. Reuben, B. G., and M. L. Burstall. 1989. Generic Pharmaceuticals-the Threat: Products and Companies at Risk. A Special Report. London: Economists Advisory Group.
50. Scherer, F. M. 1970. Industrial Market Structure and Economic Performance. Chicago: Rand McNally.
51. Scherer, F. M. 1993. "Pricing, Profits, and Technological Progress in the Pharmaceutical Industry." Journal of Economic Perspectives 7, no. 3: 97-115.
52. Scherer, F. M. 1996. "Pharmaceuticals." In Industry Structure, Strategy, and Public Policy, 336-90. New York: HarperCollins.
53. Schwab, M., et al. 2002. "Using Trade Names: A Risk Factor for Accidental Drug Overdose." Archives of Internal Medicine 162, no. 13: 1065-66.
54. Silverman, M., and P. R. Lee. 1974. Pills, Profits, and Politics. Berkeley: University of California Press.
55. Sjöström, H., and R. Nilsson. 1972. Thalidomide and the Power of the Drug Companies. Harmondsworth, UK: Penguin.
56. Steele, H. 1962. "Monopoly and Competition in the Ethical Drugs Market." Journal of Law and Economics 5: 131-64.
57. Steinman, M. A., M. M. Chren, and C. S. Landefeld. 2007. "What's in a Name? Use of Brand versus Generic Drug Names in United States Outpatient Practice." Journal of General Internal Medicine 22, no. 5: 645-48.
58. Taussig, H. B. 1963. "The Evils of Camouflage as Illustrated by Thalidomide." New England Journal of Medicine 269: 92-94.
59. US Congress. 1960. Senate Committee on the Judiciary, Subcommittee on Antitrust and Monopoly (Chairman, Senator E. Kefauver). "Administered Prices in the Drug Industry," parts 14-26. Washington, DC: US GPO.
60. US Congress. 1961. Administered Prices: Drugs (The Kefauver Report), no. 448. Washington, DC: US GPO.
61. US Congress. 1967-1973. Senate Select Committee on Small Business, Subcommittee on Monopoly (Chairman, Senator G. Nelson). "Competitive Problems in the Drug Industry," parts 1-28. Washington, DC: US GPO.
62. US Congress. 1972. Senate Select Committee on Small Business, Subcommittee on Monopoly (Chairman, Senator G. Nelson). "Competitive Problems in the Drug Industry, Summary and Analysis." Washington, DC: US GPO.
63. US Congress. 1973-1974. Senate Committee on Labor and Public Welfare, Subcommittee on Health (Chairman, Senator T. Kennedy). "Examination of the Pharmaceutical Industry," parts 1-7. Washington, DC: US GPO.
64. US Food and Drug Administration. 2006. "Consumers Filling U.S. Prescriptions Abroad May Get the Wrong Active Ingredient Because of Confusing Drug Names." Public Health Advisory, January. www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm173134.htm.
65. US Task Force on Prescription Drugs. 1969. Final Report. Washington, DC: US GPO.
66. Vogler, S. 2011. "Pricing and Reimbursement of Medicines: A European Overview." Paper presented to the PPPRI Conference, Vienna, September 30. http://whocc.goeg.at/conference.
67. Walker, H. D. 1971. Market Power and Price Levels in the Ethical Drug Industry. Bloomington: Indiana University Press.
68. World Bank. 1993. World Development Report: Investing in Health. Washington, DC: World Bank.
69. World Health Organization. 1950. Expert Committee on the Unification of Pharmacopeias: Report on the Sixth Session. Technical Report Series No. 29. Geneva: WHO. www.who.int/iris/handle/10665/38948 (accessed December 23, 2012).
70. World Health Organization. 1997. Guidelines on the Use of International Nonproprietary Names (INN) for Pharmaceutical Substances. Geneva: WHO. http://apps.who.int/medicinedocs/es/d/Jh1806e (accessed December 23, 2012).
71. World Health Organization. 2002b. The Use of Common Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances. Geneva: WHO. http://whqlibdoc.who.int/hq/2003/WHO_EDM_QSM_2003.2.pdf (accessed December 23, 2012).
72. World Health Organization. 2004a. International Nonproprietary Names: Revised Procedure. Executive Board Committee 115, no. 11. Geneva: WHO.
73. World Health Organization. 2004b. WHO Medicines Strategy: Countries at the Core, 2004-2007. Geneva: WHO.
74. World Health Organization. 2012a. "Medicines. Guidance on INN." www.who.int/medicines/services/inn/innguidance/en (accessed December 23, 2012).
75. World Health Organization. 2012b. "Recommended INN List No. 68." WHO Drug Information 26, no. 3: 301-37.